Discovering novel functional markers that capture tumor biology, TME interactions, and drug response/resistance in archived tissue.
Using TAA profiling to identify differentially expressed, disease-modifying, tractable targets on the cell surface.
We touch on the key highlights related to methods used & discoveries made in our published study across >26K samples.
Why proteomics is critical to move beyond traditional known targets & biomarkers with mapping of non-canonical proteins.
How saliva proteomics enables patient-friendly trial design while delivering insights into systemic health & drug response.
See how Sapient & Rancho Biosciences have partnered to develop a clinical-molecular database combining omics & RWD at scale.
Explore advancements finally allowing drug developers to extract maximal biological insight from the plasma proteome.
Sapient joins experts from Boehringer Ingelheim, ASU, The Institute of Cancer Research, London, & SciLifeLab to discuss.
From Oxford Global's Multi-Omics Symposium, sharing examples of proteomics & metabolomics applied in drug discovery.
Explore how discovery proteomics combined with AI-based target validation can be used to match therapies to optimal targets.
How proteomics & metabolomics data gives biological and patient context to advance every phase of drug development.
Now available on demand! See the scientific innovations expanding the druggable space and enabling discovery of novel targets.
